NASDAQ:IRTC - iRhythm Technologies Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $161.17
  • Forecasted Upside: 142.57 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▲ +2.89 (4.55%)

This chart shows the closing price for IRTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New iRhythm Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRTC

Analyst Price Target is $161.17
▲ +142.57% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for iRhythm Technologies in the last 3 months. The average price target is $161.17, with a high forecast of $273.00 and a low forecast of $78.00. The average price target represents a 142.57% upside from the last price of $66.44.

This chart shows the closing price for IRTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 12 polled investment analysts is to hold stock in iRhythm Technologies. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/3/2021Morgan StanleyLower Price TargetEqual Weight$94.00 ➝ $85.00Low
6/2/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngradeBuy ➝ Neutral$105.00 ➝ $78.00High
6/2/2021Needham & Company LLCReiterated RatingHoldHigh
6/2/2021CitigroupDowngradeBuy ➝ NeutralHigh
4/20/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$288.00 ➝ $94.00High
4/19/2021BTIG ResearchReiterated RatingBuy ➝ NeutralN/A
4/14/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$288.00 ➝ $94.00High
4/13/2021TruistLower Price Target$220.00 ➝ $115.00Low
4/13/2021Truist SecuritiesLower Price TargetBuy$220.00 ➝ $115.00Medium
4/13/2021BTIG ResearchDowngradeBuy ➝ NeutralHigh
4/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$215.00 ➝ $95.00High
4/12/2021Robert W. BairdLower Price TargetNeutral$170.00 ➝ $80.00High
3/4/2021Colliers SecuritiesReiterated RatingBuy ➝ NeutralN/A
3/1/2021CitigroupLower Price TargetBuy$252.00 ➝ $195.00Low
2/28/2021Robert W. BairdReiterated RatingHoldLow
2/26/2021Colliers SecuritiesDowngradeBuy ➝ NeutralHigh
2/4/2021BTIG ResearchLower Price TargetBuy$283.00 ➝ $210.00Low
2/1/2021TruistLower Price Target$265.00 ➝ $220.00Low
1/29/2021Needham & Company LLCReiterated RatingHoldHigh
1/25/2021Morgan StanleyBoost Price TargetOverweight$227.00 ➝ $288.00High
1/21/2021BTIG ResearchBoost Price TargetBuy$235.00 ➝ $283.00High
12/15/2020Morgan StanleyLower Price TargetOverweight$230.00 ➝ $227.00High
12/10/2020William BlairReiterated RatingBuyMedium
12/3/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target$275.00 ➝ $238.00High
12/3/2020TruistLower Price Target$265.00 ➝ $240.00Medium
12/3/2020Smith Barney CitigroupLower Price Target$275.00 ➝ $238.00Medium
12/3/2020Robert W. BairdLower Price TargetNeutral$220.00 ➝ $170.00High
12/2/2020Morgan StanleyLower Price TargetOverweight$270.00 ➝ $230.00High
11/17/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
11/17/2020Needham & Company LLCReiterated RatingHoldHigh
11/6/2020TruistBoost Price Target$200.00 ➝ $265.00Low
11/6/2020Morgan StanleyBoost Price TargetOverweight$259.00 ➝ $270.00Low
11/6/2020Canaccord GenuityBoost Price TargetBuy$236.00 ➝ $273.00Medium
11/6/2020OppenheimerReiterated RatingBuy$200.00 ➝ $250.00High
10/12/2020BTIG ResearchBoost Price Target$130.00 ➝ $160.00Low
9/11/2020Needham & Company LLCInitiated CoverageHoldLow
9/1/2020Robert W. BairdInitiated CoverageNeutral$220.00Medium
8/26/2020Canaccord GenuityBoost Price TargetBuy$210.00 ➝ $236.00Low
8/25/2020CitigroupBoost Price TargetBuy$215.00 ➝ $250.00Low
8/7/2020Colliers SecuritiesUpgradeNeutral ➝ Buy$200.00High
8/5/2020Canaccord GenuityBoost Price TargetPositive ➝ Buy$130.00 ➝ $189.00High
8/5/2020CitigroupBoost Price TargetBuy$147.00 ➝ $200.00High
8/5/2020OppenheimerUpgradeMarket Perform ➝ Outperform$200.00High
5/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$125.00 ➝ $140.00Low
5/8/2020Morgan StanleyBoost Price TargetOverweight$114.00 ➝ $142.00Low
5/8/2020SunTrust BanksBoost Price TargetBuy$102.00 ➝ $130.00High
5/8/2020Canaccord GenuityBoost Price TargetBuy$107.00 ➝ $130.00High
5/8/2020BTIG ResearchReiterated RatingBuy$130.00High
5/8/2020OppenheimerReiterated RatingHoldHigh
4/13/2020Canaccord GenuityLower Price TargetBuy$112.00 ➝ $107.00High
3/27/2020Morgan StanleyBoost Price TargetOverweight$110.00 ➝ $114.00High
3/27/2020CitigroupLower Price TargetBuy$120.00 ➝ $112.00High
3/4/2020CitigroupInitiated CoverageBuy$120.00Medium
2/28/2020Canaccord GenuityBoost Price TargetBuy$107.00 ➝ $112.00Medium
2/5/2020BTIG ResearchInitiated CoverageBuy$90.00Low
1/9/2020William BlairInitiated CoverageOutperformHigh
1/7/2020SunTrust BanksInitiated CoverageBuy$102.00High
12/24/2019Canaccord GenuityReiterated RatingBuy$107.00Low
12/17/2019Morgan StanleyBoost Price TargetOverweight$101.00 ➝ $110.00Low
10/22/2019OppenheimerInitiated CoverageMarket PerformLow
8/1/2019JPMorgan Chase & Co.Boost Price TargetOverweight$110.00 ➝ $125.00High
7/31/2019BTIG ResearchSet Price TargetBuy$90.00N/A
5/8/2019BTIG ResearchBoost Price TargetPositive ➝ Buy$90.00High
4/3/2019BTIG ResearchUpgradeNeutral ➝ Buy$80.00Medium
2/20/2019Chardan CapitalDowngradeBuy ➝ Neutral$111.00 ➝ $104.00Low
2/13/2019Royal Bank of CanadaBoost Price TargetOutperform$109.00Low
2/13/2019JPMorgan Chase & Co.Boost Price Target$110.00Low
2/13/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$85.00 ➝ $101.00Medium
2/13/2019Northland SecuritiesReiterated RatingHold$75.00High
2/13/2019BTIG ResearchReiterated RatingHoldMedium
2/13/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$96.00 ➝ $105.00High
2/13/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$90.00 ➝ $104.00High
1/11/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$84.00 ➝ $90.00Low
10/11/2018Morgan StanleyBoost Price TargetOverweight$92.00 ➝ $95.00High
9/13/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$93.00 ➝ $100.00Low
9/6/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$117.00Medium
8/2/2018Dougherty & CoUpgradeSell ➝ NeutralHigh
8/2/2018BTIG ResearchReiterated RatingHoldHigh
8/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$86.00 ➝ $92.00High
8/2/2018JPMorgan Chase & Co.Reiterated RatingOverweight$100.00High
8/2/2018Canaccord GenuityReiterated RatingBuy$93.00High
8/2/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$93.00 ➝ $96.00High
7/16/2018Dougherty & CoDowngradeNeutral ➝ SellMedium
7/10/2018BMO Capital MarketsBoost Price TargetOutperform$93.00High
6/13/2018Royal Bank of CanadaBoost Price TargetOutperform$91.00Medium
6/4/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $86.00Low
4/16/2018Northland SecuritiesReiterated RatingHold$60.00Low
3/14/2018Northland SecuritiesReiterated RatingHold$60.00Low
3/12/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$68.00 ➝ $80.00Low
3/5/2018BMO Capital MarketsInitiated CoverageOutperform$76.00Medium
2/15/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$62.00 ➝ $67.00High
12/4/2017Royal Bank of CanadaInitiated CoverageOutperform$79.00High
12/1/2017Dougherty & CoInitiated CoverageNeutral ➝ NeutralMedium
11/14/2017Canaccord GenuityReiterated RatingBuy$59.00N/A
11/3/2017Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $65.00N/A
11/2/2017Canaccord GenuityBoost Price TargetBuy$55.00 ➝ $59.00N/A
9/22/2017Canaccord GenuityBoost Price TargetBuy$49.00 ➝ $55.00High
6/6/2017Canaccord GenuityReiterated RatingBuy$42.00Medium
6/6/2017Morgan StanleyBoost Price TargetOverweight$43.00 ➝ $47.00High
5/15/2017Canaccord GenuityReiterated RatingBuy$42.00N/A
5/5/2017Canaccord GenuityReiterated RatingBuy$42.00Low
4/10/2017Canaccord GenuityReiterated RatingBuy$40.00Low
12/6/2016BTIG ResearchDowngradeBuy ➝ NeutralN/A
11/14/2016Morgan StanleyInitiated CoverageOverweight$28.00N/A
11/14/2016Canaccord GenuityInitiated CoverageBuy$31.00N/A
11/14/2016BTIG ResearchInitiated CoverageBuy$28.00N/A
11/14/2016JPMorgan Chase & Co.Initiated CoverageOverweight$34.00N/A
(Data available from 6/24/2016 forward)
iRhythm Technologies logo
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $66.44
Low: $63.89
High: $67.29

50 Day Range

MA: $73.53
Low: $61.80
High: $90.94

52 Week Range

Now: $66.44
Low: $59.64
High: $286.19


542,493 shs

Average Volume

715,261 shs

Market Capitalization

$1.95 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of iRhythm Technologies?

The following Wall Street sell-side analysts have issued research reports on iRhythm Technologies in the last twelve months: BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Colliers Securities, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, Smith Barney Citigroup, TheStreet, Truist, Truist Securities, William Blair, and Zacks Investment Research.
View the latest analyst ratings for IRTC.

What is the current price target for iRhythm Technologies?

12 Wall Street analysts have set twelve-month price targets for iRhythm Technologies in the last year. Their average twelve-month price target is $161.17, suggesting a possible upside of 153.6%. Canaccord Genuity has the highest price target set, predicting IRTC will reach $273.00 in the next twelve months. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the lowest price target set, forecasting a price of $78.00 for iRhythm Technologies in the next year.
View the latest price targets for IRTC.

What is the current consensus analyst rating for iRhythm Technologies?

iRhythm Technologies currently has 9 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IRTC, but not buy more shares or sell existing shares.
View the latest ratings for IRTC.

What other companies compete with iRhythm Technologies?

How do I contact iRhythm Technologies' investor relations team?

iRhythm Technologies' physical mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company's listed phone number is 415-632-5700 and its investor relations email address is [email protected] The official website for iRhythm Technologies is